Thymosin alpha 1 potentiates interleukin 2-induced cytotoxic activity in mice.
Mastino. A A; Favalli. C C; Grelli. S S; Innocenti. F F; Garaci. E E
Key Findings
- Thymosin‑alpha‑1 pretreatment (100 ng/ml in vitro or 200 µg/kg/day for 4 days in vivo) significantly increased IL‑2‑driven cytotoxic activity of spleen lymphocytes
- The enhancement was seen in normal mice, mice treated with cyclophosphamide, and mice bearing B‑16 melanoma
- Both NK‑sensitive (YAC‑1) and NK‑resistant (MBL‑2) target cells were more effectively killed
Practical Outcomes
- For biohackers, the study hints that pairing thymosin‑alpha‑1 with IL‑2 might amplify immune‑killing effects, but the evidence is limited to mice and uses high doses. Human dosing, safety, and the practicality of obtaining IL‑2 remain major hurdles, so any self‑experiment should proceed with caution and preferably under medical supervision.
Summary
In mice, giving thymosin‑alpha‑1 before interleukin‑2 makes immune cells better at killing cancer‑like cells, even in animals weakened by chemotherapy or tumors. The boost works for both easy‑to‑kill and harder‑to‑kill target cells, suggesting the two compounds together could act as a stronger immune‑stimulating combo.
Abstract
We have investigated the effects of interleukin 2 (IL-2) on cytotoxic activity of spleen lymphocytes, from normal and cyclophosphamide (200 mg/kg) or B-16 melanoma suppressed mice, after in vitro or in vivo pretreatment with thymosin alpha 1 (TA1). The results of this study indicate that pretreatment in vitro (100 ng/ml for 1 hr) or in vivo (200 micrograms/kg/day for 4 days) with thymosin alpha 1 (TA1), significantly increased the IL-2 (from 100 to 500 U/ml) in vitro induced cytotoxic activity of spleen lymphocytes, collected from both normal and cyclophosphamide and tumor-suppressed animals, against both YAC-1 (NK sensitive) and MBL-2 (NK resistant) cell lines. The potential use in combination of these two different biological response modifiers, useful in enhancing the immunological responses to IL-2 of lymphocytes, may provide a novel model of immunotherapeutic intervention in cancer.
Study Information
pubmed
1991
10.1016/0008-8749(91)90191-d